Why Apex Doesn't Use BMAC or Adipose-Derived Stem Cells

This is a position paper. It's the cleanest way to explain a clinical choice that comes up in nearly every consultation: "If other clinics are using bone marrow or fat-derived stem cells, why don't you?"

The short version: we think the biology, the regulatory landscape, and the patient experience all favor screened allogeneic umbilical-derived MSCs over autologous BMAC or adipose-derived options for the indications we treat. None of that means BMAC or adipose are useless or that good clinicians using them are doing bad medicine. It means we landed somewhere different after looking at the same evidence, and we want patients to understand why.

The biology favors young donor cells

Mesenchymal stem cells age along with the body they're in. The MSCs in a 65-year-old patient's iliac crest aren't biologically equivalent to MSCs from screened umbilical tissue. Multiple cell-biology studies over the last 20 years have shown:

• Older MSCs have shorter telomeres
• They proliferate more slowly in culture
• They release fewer of the growth factors and signaling molecules that drive the paracrine repair effect we care about
• They differentiate less efficiently toward chondrogenic lineages

The clinical translation isn't a 1:1 ratio (you can't say "umbilical cells work twice as well"), but the underlying potency advantage is real and consistent. When the protocol's effectiveness depends substantially on the cell's signaling output, younger source cells start with a head start.

Adipose-derived cells inherit the same patient-age problem. The convenience of harvest (a small liposuction) doesn't compensate for the biological reality.

Cell yield and consistency

A bone marrow aspirate from one patient is not the same as a bone marrow aspirate from another. Yield varies dramatically based on:

• Age
• Underlying inflammatory state
• Aspiration technique and volume
• Time and processing between draw and use

The same is true for adipose harvests. The end concentration of viable MSCs in a BMAC or SVF preparation is variable in ways the operator can't fully control.

Screened allogeneic products are different. They come in a known cell count per vial, with documentation. We can write a protocol that says "1.5 x 10^7 MSCs intra-articular" and actually deliver that dose, predictably, across patients.

For research, variable dosing is a problem because it confounds outcome measures. For clinical work, it's a problem because the patient is paying for a specific result and we should know what we're delivering.

The regulatory framework

The FDA divides cellular products into two pathways under 21 CFR 1271: "361" products (minimally manipulated, intended for homologous use) and "351" products (drug-like, requiring approval).

Allogeneic umbilical MSCs from FDA-registered processors can meet the 361 criteria when handled correctly: minimal manipulation, homologous use, screened donor, established tissue establishment registration.

Adipose-derived stem cells via SVF processing (enzymatic digestion with collagenase) have been considered by FDA to constitute more-than-minimal manipulation in many configurations, pushing them into the 351 pathway. Most clinics offering SVF are not registered for 351 manufacturing. This has created an ongoing regulatory gray zone that we don't think is the right place to set up shop.

BMAC sits in a clearer regulatory position when used at the point of care without significant manipulation, but the biology still has the patient-age problem.

We chose a path that's clean on both axes. Strong biology, clean regulatory pathway, documentable product.

The patient experience

Harvesting bone marrow requires a separate procedure. It's done with local anesthesia, but it's still a needle into the iliac crest, with associated soreness for several days. Adipose harvest is a mini-lipo procedure, also under local anesthesia, with similar transient discomfort.

Allogeneic injection doesn't require either step. You arrive for the injection, the cells are prepared and dosed, and you receive the protocol. One procedure, not two.

For some patients this is purely a convenience question. For older or frailer patients, or patients on blood thinners that complicate aspiration, it's substantive.

Cost

A common assumption is that autologous protocols are cheaper because there's no third-party product cost. In practice, the harvest itself adds time, materials, and operator cost. Pricing for BMAC and SVF protocols in the DFW market is broadly comparable to ours for allogeneic protocols, sometimes higher, sometimes a little lower.

We don't think there's a material cost advantage that would justify the biological trade-off.

What we'd reconsider for

This isn't a position we hold out of inertia. If the evidence shifts in specific directions, we'd revisit.

Specifically, we'd reconsider BMAC for:

• Certain cartilage repair surgical augmentation contexts where the surgical literature has stronger data
• Specific spine fusion indications where it's already established
• A future RCT comparing BMAC head-to-head with allogeneic umbilical MSCs in a well-controlled trial that shows BMAC superiority

We'd reconsider adipose for:

• A clear evidence base in a specific indication that allogeneic products don't address
• A regulatory clarification that aligned with whichever processing pathway delivers the cell type

So far, neither set of conditions has emerged for the indications we treat.

The honest summary

You can do this work well with autologous bone marrow or adipose-derived cells, and there are clinicians who do. We made a different call. Younger donor cells with documentable dose and a clean regulatory pathway looked like the better starting point for the kind of practice we wanted to run.

If you've been quoted a BMAC or SVF protocol elsewhere and want a second opinion on whether the choice fits your case, request a consultation. We'll tell you when we think their plan is reasonable and when we think there's a stronger option.